Beijing Cancer Hospital ( Site 0155)

Beijing, Beijing Municipality 100142

0 studies enrolling now · 1 studies all time

What they study most

Hepatocellular Carcinoma

Studies at this site

• Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937) — Completed